(Q44883692)

7 December 2017

title

Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy (English)

1 reference

7 December 2017

0 references

1 reference

cervix uterine cancer

1 reference

Kavanagh BD

1

1 reference

7 December 2017

Fischer BA 4th

2

1 reference

7 December 2017

Segreti EM

3

1 reference

7 December 2017

Wheelock JB

4

1 reference

7 December 2017

Boardman C

5

1 reference

7 December 2017

Roseff SD

6

1 reference

7 December 2017

Cardinale RM

7

1 reference

7 December 2017

Benedict SH

8

1 reference

7 December 2017

Goram AL

9

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

International Journal of Radiation Oncology Biology Physics

7 December 2017

published in

1 reference

7 December 2017

volume

51

1 reference

7 December 2017

issue

2

1 reference

7 December 2017

page(s)

435-441

1 reference

The significance of anemia in clinical radiation therapy

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Anemia, hypoxia and transfusion in patients with cervix cancer: a review.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and tetraplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Erythropoietin increases hemoglobin during radiation therapy for cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Erythropoietin increases hemoglobin in cancer patients during radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

IgA anaphylactic transfusion reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Costs of HIV medical care in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

The economic burden of hepatitis B in Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

A cost-effectiveness analysis of epoetin usage for patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

A cost analysis comparing erythropoietin and red cell transfusions in the treatment of anemia of prematurity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

The effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Erythropoietin-induced rheological changes of rat erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Changes of blood oxygen affinity in different CPD solutions during liquid storage

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

NAT of the United States and Canadian blood supply

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Transfusion medicine. First of two parts--blood transfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

Universal WBC reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

NAT and blood safety: what is the paradigm?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901645-5

7 January 2021

10.1016/S0360-3016(01)01645-5

Identifiers

DOI

1 reference

7 December 2017

1 reference